Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retifanlimab alone or in combination in advanced/metastatic endometrial cancer (POD1UM-204)
NCT04463771Phase 2Completed
- Sponsor
- Incyte
- Start
- Jan 2021
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of retifanlimab in endometrial cancer (EC), sponsored by Incyte. Started Jan 2021; status: completed.
02
Drugs
retifanlimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT04463771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04463771.